Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tenofovir · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Twice daily | OTHER | Tenofovir gel intravaginal twice daily for 14 days |
| Once daily | OTHER | Tenofovir gel intravaginal once daily for 14 days |
| Name | Type | Description |
|---|---|---|
| Tenofovir gel | DRUG | Intravaginal (4grams)single dose followed by fourteen days |
| Tenofovir | DRUG | - |
Inclusion Criteria: * Must be between 18-45 years old, inclusive * Must be in general good health by volunteer history without any clinically significant systemic disease (including liver disease/hepatitis, gastrointestinal disease, kidney disease, thyroid disease, osteoporosis or bone disease) * M...
Top 20 of 28 competitors
Tenofovir is a small molecule being developed by Gilead Sciences, Inc. for the treatment of HIV Infections. It is currently in Phase 1 clinical development, meaning it is investigational and has not yet been approved for use. The drug is being studied in clinical trials to evaluate its safety and pharmacokinetics in HIV-infected patients.
Tenofovir is a small molecule drug being developed for HIV Infections. As a small molecule, it is designed to interfere with viral replication. However, the specific molecular target or target class has not been specified in the available information. The drug is currently in Phase 1 clinical trials to assess its safety and how it is processed by the body.
Tenofovir is being developed by Gilead Sciences, Inc., a biopharmaceutical company listed on the NASDAQ under the ticker symbol GILD. The company is conducting clinical trials to evaluate the drug for the treatment of HIV Infections. Tenofovir is currently in Phase 1 development, indicating it is still in the early stages of clinical testing.
Tenofovir is currently in Phase 1 clinical development. It is an investigational drug being studied for the treatment of HIV Infections. The drug has completed two Phase 1 trials, with a total enrollment of 49 participants. Tenofovir is not yet approved by regulatory authorities and remains in the early stages of clinical testing.
Tenofovir has been studied in two completed Phase 1 clinical trials. The first trial, NCT00002180, was a study of PMPA in HIV-infected patients in the United States. The second trial, NCT00561496, was a pharmacokinetic study of a vaginal microbicide gel containing 1% tenofovir, conducted in the United States and Dominican Republic with 49 female participants.
Tenofovir is also known as PMPA, as indicated by the clinical trial NCT00002180, which was titled 'A Study of PMPA in HIV-Infected Patients'. This trial was a Phase 1 study conducted in the United States to evaluate the drug in HIV-infected patients. Tenofovir is being developed by Gilead Sciences, Inc. for the treatment of HIV Infections.